gastroparesis
(2)
Neurogastrx, Inc.
Neurogastrx is a Woburn, Massachusetts biopharmaceutical company developing therapies for gastrointestinal disorders rooted in the enteric nervous system. Its lead candidate, NG101, is an oral, peripherally acting dopamine D2 receptor antagonist (a proprietary mesylate salt of metopimazine) in late-stage development for gastroparesis and for the nausea and vomiting that limit GLP-1 weight-loss and diabetes drugs. Backed by roughly $105-125M from OrbiMed, 5AM Ventures and venBio, the company reported Phase 2 data in 2025 showing sizable reductions in GLP-1-induced nausea and vomiting.
G-Tech Medical
G-Tech Medical builds the GutTracker, a thin wireless wearable patch its team calls an 'EKG for the Gut.' Worn on the abdomen for up to six days at home, the patch reads the faint electrical signals that drive the stomach, small intestine, and colon, then streams them over Bluetooth to the cloud, where algorithms turn the noise into patient-specific motility data. The Mountain View company aims to replace short, single-organ, in-clinic tests with continuous, whole-gut measurement so physicians can finally see how a digestive system actually behaves day to day.